<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424501</url>
  </required_header>
  <id_info>
    <org_study_id>114886</org_study_id>
    <nct_id>NCT01424501</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease</brief_title>
  <official_title>Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 When Administered to Adults With TB Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will assess the safety and immunogenicity of GSK Biologicals' investigational
      tuberculosis (TB) vaccine (GSK 692342) compared to placebo when administered at 0, 1 months
      to human immunodeficiency virus (HIV) negative adults who have received treatment for TB
      disease (denoted TB-treated cohort) or are currently receiving treatment for TB disease
      (denoted TB-treatment cohort). For comparative purposes, subjects who have never had TB
      disease (denoted TB-naïve cohort) will also be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Protocol Amendment 1, May 2012, was made following the decision to add a second country in
      the study (i.e. Estonia).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to a safety signal found at a planned interim safety review, further conduct of this safety
    study is not recommended hence the study was terminated.
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Solicited Local Symptoms</measure>
    <time_frame>During the 7 day (Days 0-6), after each vaccine dose</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling. They were assessed after each dose (Dose 1 = D1, Dose 2 = D2) and across doses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms</measure>
    <time_frame>During the 7 day (Days 0-6), after each vaccine dose</time_frame>
    <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, malaise, myalgia and temperature [body temperature equal to or above 37.5 degrees Celsius (°C)]. The symptoms were assessed after each dose (Dose 1 = D1, Dose 2 = D2) and across doses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs)</measure>
    <time_frame>During the 30 day (Days 0-29), after vaccination</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to day 210</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-mycobacterium Tuberculosis Fusion Protein M72 Antibodies</measure>
    <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Day 30 - D30), post-dose 2 (Days 60 - D60 and 210 - D210)</time_frame>
    <description>Cut-off values assessed were greater than or equal to 2.8, measured by ELISA (Enzyme Linked Immunosorbent Assay) in the sera of subjects seronegative before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of Mycobacterium Tuberculosis Fusion Protein M72</measure>
    <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Day 30 - D30), post-dose 2 (Days 60 - D60 and 210 - D210)</time_frame>
    <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of the Different Immune Markers</measure>
    <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)</time_frame>
    <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing 2 or More Immune Markers Among 6</measure>
    <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)</time_frame>
    <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a), CD40-ligand (CD40-L), Interleukin-17 (IL-17) and/or Interleukin-17 (IL-17).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</measure>
    <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)</time_frame>
    <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing at Least 2 Immune Markers</measure>
    <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)</time_frame>
    <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing 2 or More Immune Markers Among 6</measure>
    <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)</time_frame>
    <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a), CD40-ligand (CD40-L), Interleukin-17 (IL-17) and/or Interleukin-17 (IL-17).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</measure>
    <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 - D7 and 30 - D30), post-dose 2 (Days 37 - D37, 60 - D60 and 210 - D210)</time_frame>
    <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects from TB-treated cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects from TB-treated cohort will receive 2 doses of physiological Saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects from TB-treatment cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects from TB-treatment cohort will receive 2 doses of physiological Saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects from TB-naive cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects from TB-naive cohort will receive 2 doses of physiological Saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' investigational TB vaccine GSK 692342</intervention_name>
    <description>Intramuscular injection, 2 doses</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection, 2 doses</description>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol.

          -  A male or female between, and including, 18 and 59 years of age at the time of the
             first vaccination.

          -  Written informed consent obtained from the subject.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

               -  has practiced adequate contraception for 30 days prior to vaccination, and

               -  has a negative pregnancy test on the day of vaccination, and

               -  has agreed to continue adequate contraception during the entire treatment period
                  and for 2 months after completion of the vaccination series.

          -  Seronegative for HIV- 1 and -2 antibodies.

          -  No history of or current extrapulmonary tuberculosis TB. Additionally, based on
             medical history,

          -  Subjects in the TB-naive cohort must

               -  have no active pulmonary disease as indicated by chest X-ray.

               -  have no signs and symptoms of TB.

               -  have no history of chemoprophylaxis or treatment for TB.

          -  Subjects in the TB-treated cohort must

               -  have a history of successful treatment for pulmonary TB (completed at least 1
                  year prior to vaccination).

               -  have no active pulmonary disease on chest X-ray.

          -  Subjects in the TB-treatment cohort must - have documented treatment for pulmonary TB
             (smear- or culture confirmed) ongoing for 2-4 months prior to vaccination.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.

          -  Administration of a registered live vaccine not foreseen by the study within 30 days
             preceding the first dose of study vaccine and administration of a registered
             inactivated vaccine within 14 days preceding the first dose of study vaccine.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Any chronic drug therapy to be continued during the study period, which in the opinion
             of the investigator could adversely interfere with the vaccine.

          -  History of previous administration of experimental TB vaccines.

          -  History of previous exposure to components of the investigational vaccine within 30
             days preceding the first dose of study vaccine.

          -  Administration of any immunoglobulins, any immunotherapy and/or any blood products
             within the 3 months preceding the first dose of study vaccination, or planned
             administrations during the study period.

          -  Planned participation or participation in another experimental protocol during the
             study period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination.

          -  History of chronic alcohol and/or drug abuse.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine.

          -  Major congenital defects.

          -  Pregnant female, lactating female or female planning to become pregnant or discontinue
             contraceptive precautions during the active phase of the study (from study start till
             2 months after dose 2).

          -  Additionally, for the TB naïve and TB treated cohorts:

             - Acute or chronic clinically relevant pulmonary, cardiovascular, hepatic or renal
             function abnormality as determined by physical examination or laboratory screening
             tests

          -  Additionally, for the TB treatment cohort:

               -  Acute or chronic clinically relevant pulmonary, cardiovascular, hepatic or renal
                  function abnormality as determined by physical examination or laboratory
                  screening tests. Individuals with grade 3 levels will be excluded.

               -  Failure to convert while on anti-TB treatment at the end of the second month of
                  anti-TB therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taoyuan Hsien</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <results_first_submitted>November 29, 2016</results_first_submitted>
  <results_first_submitted_qc>November 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 24, 2017</results_first_posted>
  <disposition_first_submitted>May 29, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 29, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 2, 2014</disposition_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis vaccine</keyword>
  <keyword>HIV-negative</keyword>
  <keyword>tuberculosis treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>During the screening the following was performed: informed consent was obtained and signed from parents or guardians of subjects, check for inclusion/exclusion criteria and contraindications/precautions, and medical history of subjects was collected. Prior to vaccination, subjects’ pre-vaccination body temperature was evaluated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TB Treatment GSK 692342 Group</title>
          <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="P2">
          <title>TB Treatment Saline Group</title>
          <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="P3">
          <title>TB Treated GSK 692342 Group</title>
          <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="P4">
          <title>TB Treated Saline Group</title>
          <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="P5">
          <title>TB Naive GSK 692342 Group</title>
          <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="P6">
          <title>TB Naive Saline Group</title>
          <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="25"/>
                <participants group_id="P5" count="40"/>
                <participants group_id="P6" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TB Treatment GSK 692342 Group</title>
          <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="B2">
          <title>TB Treatment Saline Group</title>
          <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="B3">
          <title>TB Treated GSK 692342 Group</title>
          <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="B4">
          <title>TB Treated Saline Group</title>
          <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="B5">
          <title>TB Naive GSK 692342 Group</title>
          <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="B6">
          <title>TB Naive Saline Group</title>
          <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="40"/>
            <count group_id="B6" value="40"/>
            <count group_id="B7" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.9" spread="11.5"/>
                    <measurement group_id="B2" value="44.7" spread="11.8"/>
                    <measurement group_id="B3" value="44.5" spread="10.3"/>
                    <measurement group_id="B4" value="47" spread="9.8"/>
                    <measurement group_id="B5" value="33.8" spread="8.5"/>
                    <measurement group_id="B6" value="33.3" spread="9.8"/>
                    <measurement group_id="B7" value="38.7" spread="9.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling. They were assessed after each dose (Dose 1 = D1, Dose 2 = D2) and across doses.</description>
        <time_frame>During the 7 day (Days 0-6), after each vaccine dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with study vaccine administered and for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms were pain, redness and swelling. They were assessed after each dose (Dose 1 = D1, Dose 2 = D2) and across doses.</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with study vaccine administered and for whom data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain, D1 (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, D1 (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, D1 (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, D2 (N=6,5,21,25,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, D2 (N=6,5,21,25,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, D2 (N=6,5,21,25,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain, Across (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness, Across (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling, Across (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, malaise, myalgia and temperature [body temperature equal to or above 37.5 degrees Celsius (°C)]. The symptoms were assessed after each dose (Dose 1 = D1, Dose 2 = D2) and across doses.</description>
        <time_frame>During the 7 day (Days 0-6), after each vaccine dose</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with study vaccine administered and for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, malaise, myalgia and temperature [body temperature equal to or above 37.5 degrees Celsius (°C)]. The symptoms were assessed after each dose (Dose 1 = D1, Dose 2 = D2) and across doses.</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with study vaccine administered and for whom data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue, D1 (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms, D1 (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, D1 (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise, D1 (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, D1 (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature/(Axillary), D1 (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, D2 (N=6,5,21,25,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms, D2 (N=6,5,21,25,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, D2 (N=6,5,21,25,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise, D2 (N=6,5,21,25,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, D2 (N=6,5,21,25,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature/(Axillary), D2 (N=6,5,21,25,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, Across (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms,Across(N=7,6,24,25,40,40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, Across (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise, Across (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, Across (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature/(Axillary), Across (N=7,6,24,25,40,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Adverse Events (AEs)</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>During the 30 day (Days 0-29), after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with study vaccine administered and for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events (AEs)</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with study vaccine administered and for whom data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>Up to day 210</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with study vaccine administered and for whom data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The analysis was performed on the Total Vaccinated cohort which included all subjects with study vaccine administered and for whom data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-mycobacterium Tuberculosis Fusion Protein M72 Antibodies</title>
        <description>Cut-off values assessed were greater than or equal to 2.8, measured by ELISA (Enzyme Linked Immunosorbent Assay) in the sera of subjects seronegative before vaccination.</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Day 30 – D30), post-dose 2 (Days 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-mycobacterium Tuberculosis Fusion Protein M72 Antibodies</title>
          <description>Cut-off values assessed were greater than or equal to 2.8, measured by ELISA (Enzyme Linked Immunosorbent Assay) in the sera of subjects seronegative before vaccination.</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-M72, PRE (N=7,4,21,25,37,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-M72, D30 (N=6,4,21,25,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="26"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-M72, D60 (N=6,3,19,25,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-M72, D210 (N=6,3,19,25,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations of Mycobacterium Tuberculosis Fusion Protein M72</title>
        <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Day 30 – D30), post-dose 2 (Days 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Mycobacterium Tuberculosis Fusion Protein M72</title>
          <description>Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EU/mL).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-M72, PRE (N=7,4,21,25,37,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O3" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O4" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O5" value="1.4" lower_limit="1.4" upper_limit="1.5"/>
                    <measurement group_id="O6" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-M72, D30 (N=6,4,21,25,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="2.1" upper_limit="21"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O3" value="11.7" lower_limit="6.3" upper_limit="22"/>
                    <measurement group_id="O4" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O5" value="4.5" lower_limit="3.3" upper_limit="6.2"/>
                    <measurement group_id="O6" value="1.5" lower_limit="1.4" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-M72, D60 (N=6,3,19,25,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.6" lower_limit="46.2" upper_limit="923.2"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O3" value="226.2" lower_limit="99" upper_limit="517.2"/>
                    <measurement group_id="O4" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O5" value="248.6" lower_limit="171" upper_limit="361.4"/>
                    <measurement group_id="O6" value="1.7" lower_limit="1.3" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-M72, D210 (N=6,3,19,25,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.4" lower_limit="18.9" upper_limit="77.9"/>
                    <measurement group_id="O2" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O3" value="50.9" lower_limit="27.3" upper_limit="94.8"/>
                    <measurement group_id="O4" value="1.4" lower_limit="1.4" upper_limit="1.4"/>
                    <measurement group_id="O5" value="45.6" lower_limit="34.2" upper_limit="60.8"/>
                    <measurement group_id="O6" value="1.4" lower_limit="1.4" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of the Different Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of the Different Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4-ALL doubles, PRE (N=4,3,15,22,30,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247" lower_limit="204.5" upper_limit="333.5"/>
                    <measurement group_id="O2" value="178" lower_limit="70" upper_limit="651"/>
                    <measurement group_id="O3" value="347" lower_limit="196" upper_limit="523"/>
                    <measurement group_id="O4" value="549.5" lower_limit="375" upper_limit="997"/>
                    <measurement group_id="O5" value="286" lower_limit="173" upper_limit="471"/>
                    <measurement group_id="O6" value="352" lower_limit="170" upper_limit="579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-ALL doubles, D7 (N=4,3,13,15,26,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="997.5" lower_limit="714" upper_limit="1345"/>
                    <measurement group_id="O2" value="182" lower_limit="82" upper_limit="431"/>
                    <measurement group_id="O3" value="1097" lower_limit="985" upper_limit="1760"/>
                    <measurement group_id="O4" value="469" lower_limit="328" upper_limit="1075"/>
                    <measurement group_id="O5" value="801.5" lower_limit="440" upper_limit="1492"/>
                    <measurement group_id="O6" value="265.5" lower_limit="167.5" upper_limit="571.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-ALL doubles, D30 (N=5,2,16,16,34,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2959" lower_limit="1289" upper_limit="2989"/>
                    <measurement group_id="O2" value="730" lower_limit="216" upper_limit="1244"/>
                    <measurement group_id="O3" value="2616.5" lower_limit="1417" upper_limit="5614"/>
                    <measurement group_id="O4" value="466" lower_limit="261.5" upper_limit="1145.5"/>
                    <measurement group_id="O5" value="1228.5" lower_limit="941" upper_limit="2131"/>
                    <measurement group_id="O6" value="312.5" lower_limit="202" upper_limit="726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-ALL doubles, D37 (N=5,3,18,19,34,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4433" lower_limit="3024" upper_limit="10010"/>
                    <measurement group_id="O2" value="273" lower_limit="221" upper_limit="445"/>
                    <measurement group_id="O3" value="5705.5" lower_limit="2219" upper_limit="11228"/>
                    <measurement group_id="O4" value="533" lower_limit="227" upper_limit="1235"/>
                    <measurement group_id="O5" value="5987.5" lower_limit="3987" upper_limit="9605"/>
                    <measurement group_id="O6" value="247" lower_limit="175" upper_limit="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-ALL doubles, D60 (N=4,2,15,18,31,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5648" lower_limit="3686" upper_limit="7957"/>
                    <measurement group_id="O2" value="241" lower_limit="224" upper_limit="258"/>
                    <measurement group_id="O3" value="2072" lower_limit="1083" upper_limit="4199"/>
                    <measurement group_id="O4" value="517" lower_limit="352" upper_limit="1242"/>
                    <measurement group_id="O5" value="5153" lower_limit="2884" upper_limit="8978"/>
                    <measurement group_id="O6" value="240" lower_limit="146" upper_limit="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4-ALL doubles, D210 (N=6,3,13,17,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2922.5" lower_limit="967" upper_limit="4411"/>
                    <measurement group_id="O2" value="118" lower_limit="116" upper_limit="307"/>
                    <measurement group_id="O3" value="1154" lower_limit="1028" upper_limit="1808"/>
                    <measurement group_id="O4" value="445" lower_limit="243" upper_limit="734"/>
                    <measurement group_id="O5" value="2155" lower_limit="1389" upper_limit="4160"/>
                    <measurement group_id="O6" value="254" lower_limit="166" upper_limit="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing 2 or More Immune Markers Among 6</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a), CD40-ligand (CD40-L), Interleukin-17 (IL-17) and/or Interleukin-17 (IL-17).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing 2 or More Immune Markers Among 6</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a), CD40-ligand (CD40-L), Interleukin-17 (IL-17) and/or Interleukin-17 (IL-17).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD4-At least 2, PRE (N=4,3,15,22,30,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260" lower_limit="217.5" upper_limit="346.5"/>
                    <measurement group_id="O2" value="207" lower_limit="96" upper_limit="687"/>
                    <measurement group_id="O3" value="364" lower_limit="238" upper_limit="536"/>
                    <measurement group_id="O4" value="562.5" lower_limit="402" upper_limit="1010"/>
                    <measurement group_id="O5" value="325" lower_limit="240" upper_limit="512"/>
                    <measurement group_id="O6" value="365" lower_limit="214" upper_limit="609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4- At least 2, D7 (N=4,3,13,15,26,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1010.5" lower_limit="733.5" upper_limit="1358"/>
                    <measurement group_id="O2" value="208" lower_limit="95" upper_limit="457"/>
                    <measurement group_id="O3" value="1152" lower_limit="1011" upper_limit="1895"/>
                    <measurement group_id="O4" value="482" lower_limit="347" upper_limit="1088"/>
                    <measurement group_id="O5" value="856" lower_limit="479" upper_limit="1505"/>
                    <measurement group_id="O6" value="278.5" lower_limit="193.5" upper_limit="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4- At least 2, D30 (N=5,2,16,16,34,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2972" lower_limit="1302" upper_limit="3002"/>
                    <measurement group_id="O2" value="765" lower_limit="229" upper_limit="1301"/>
                    <measurement group_id="O3" value="2636" lower_limit="1437" upper_limit="5655"/>
                    <measurement group_id="O4" value="497" lower_limit="282" upper_limit="1179"/>
                    <measurement group_id="O5" value="1248.5" lower_limit="954" upper_limit="2144"/>
                    <measurement group_id="O6" value="348.5" lower_limit="238" upper_limit="754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4- At least 2, D37 (N=5,3,18,19,34,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4446" lower_limit="3037" upper_limit="10107"/>
                    <measurement group_id="O2" value="316" lower_limit="234" upper_limit="458"/>
                    <measurement group_id="O3" value="5733.5" lower_limit="2232" upper_limit="11281"/>
                    <measurement group_id="O4" value="565" lower_limit="260" upper_limit="1262"/>
                    <measurement group_id="O5" value="6051.5" lower_limit="4191" upper_limit="9679"/>
                    <measurement group_id="O6" value="277.5" lower_limit="190" upper_limit="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4- At least 2, D60 (N=4,2,15,18,31,32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5661" lower_limit="3699" upper_limit="7976.5"/>
                    <measurement group_id="O2" value="254" lower_limit="237" upper_limit="271"/>
                    <measurement group_id="O3" value="2101" lower_limit="1115" upper_limit="4275"/>
                    <measurement group_id="O4" value="583" lower_limit="378" upper_limit="1256"/>
                    <measurement group_id="O5" value="5185" lower_limit="2897" upper_limit="9031"/>
                    <measurement group_id="O6" value="258" lower_limit="160.5" upper_limit="496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4- At least 2, D210 (N=6,3,13,17,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2948.5" lower_limit="993" upper_limit="4670"/>
                    <measurement group_id="O2" value="131" lower_limit="129" upper_limit="320"/>
                    <measurement group_id="O3" value="1167" lower_limit="1041" upper_limit="1821"/>
                    <measurement group_id="O4" value="480" lower_limit="298" upper_limit="770"/>
                    <measurement group_id="O5" value="2269" lower_limit="1419" upper_limit="4173"/>
                    <measurement group_id="O6" value="299" lower_limit="201.5" upper_limit="449.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.5" lower_limit="68" upper_limit="134"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="252"/>
                    <measurement group_id="O3" value="87" lower_limit="34" upper_limit="140"/>
                    <measurement group_id="O4" value="124" lower_limit="74" upper_limit="186"/>
                    <measurement group_id="O5" value="60" lower_limit="4" upper_limit="108"/>
                    <measurement group_id="O6" value="54" lower_limit="17" upper_limit="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267.5" lower_limit="218.5" upper_limit="493.5"/>
                    <measurement group_id="O2" value="42" lower_limit="4" upper_limit="241"/>
                    <measurement group_id="O3" value="329" lower_limit="140" upper_limit="454"/>
                    <measurement group_id="O4" value="84" lower_limit="25" upper_limit="154"/>
                    <measurement group_id="O5" value="87" lower_limit="24" upper_limit="229"/>
                    <measurement group_id="O6" value="55.5" lower_limit="4" upper_limit="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1066" lower_limit="261" upper_limit="1233"/>
                    <measurement group_id="O2" value="330.5" lower_limit="33" upper_limit="628"/>
                    <measurement group_id="O3" value="776" lower_limit="341" upper_limit="1070.5"/>
                    <measurement group_id="O4" value="71" lower_limit="30.5" upper_limit="161.5"/>
                    <measurement group_id="O5" value="89.5" lower_limit="37" upper_limit="287"/>
                    <measurement group_id="O6" value="47" lower_limit="17" upper_limit="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1186" lower_limit="1084" upper_limit="1403"/>
                    <measurement group_id="O2" value="80" lower_limit="44" upper_limit="158"/>
                    <measurement group_id="O3" value="897.5" lower_limit="333" upper_limit="1123"/>
                    <measurement group_id="O4" value="87" lower_limit="52" upper_limit="135"/>
                    <measurement group_id="O5" value="436.5" lower_limit="192" upper_limit="592"/>
                    <measurement group_id="O6" value="45" lower_limit="11" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1444" lower_limit="1039" upper_limit="1615.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="417" lower_limit="87" upper_limit="815"/>
                    <measurement group_id="O4" value="132" lower_limit="73" upper_limit="171"/>
                    <measurement group_id="O5" value="436" lower_limit="219" upper_limit="826"/>
                    <measurement group_id="O6" value="31" lower_limit="4" upper_limit="130.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="585.5" lower_limit="288" upper_limit="997"/>
                    <measurement group_id="O2" value="18" lower_limit="4" upper_limit="74"/>
                    <measurement group_id="O3" value="288" lower_limit="217" upper_limit="313"/>
                    <measurement group_id="O4" value="68" lower_limit="38" upper_limit="157"/>
                    <measurement group_id="O5" value="201" lower_limit="95" upper_limit="504"/>
                    <measurement group_id="O6" value="35.5" lower_limit="18" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="4" upper_limit="22"/>
                    <measurement group_id="O2" value="55" lower_limit="4" upper_limit="93"/>
                    <measurement group_id="O3" value="25" lower_limit="4" upper_limit="48"/>
                    <measurement group_id="O4" value="20.5" lower_limit="4" upper_limit="58"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="26"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="17" upper_limit="44"/>
                    <measurement group_id="O2" value="17" lower_limit="4" upper_limit="45"/>
                    <measurement group_id="O3" value="44" lower_limit="31" upper_limit="116"/>
                    <measurement group_id="O4" value="27" lower_limit="4" upper_limit="34"/>
                    <measurement group_id="O5" value="19" lower_limit="4" upper_limit="54"/>
                    <measurement group_id="O6" value="16.5" lower_limit="4" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204" lower_limit="162" upper_limit="213"/>
                    <measurement group_id="O2" value="48" lower_limit="4" upper_limit="92"/>
                    <measurement group_id="O3" value="250" lower_limit="149.5" upper_limit="370.5"/>
                    <measurement group_id="O4" value="16" lower_limit="4" upper_limit="43"/>
                    <measurement group_id="O5" value="279.5" lower_limit="144" upper_limit="385"/>
                    <measurement group_id="O6" value="20.5" lower_limit="4" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436" lower_limit="246" upper_limit="550"/>
                    <measurement group_id="O2" value="35" lower_limit="31" upper_limit="49"/>
                    <measurement group_id="O3" value="292" lower_limit="154" upper_limit="525"/>
                    <measurement group_id="O4" value="9" lower_limit="4" upper_limit="43"/>
                    <measurement group_id="O5" value="558.5" lower_limit="250" upper_limit="884"/>
                    <measurement group_id="O6" value="4.5" lower_limit="4" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="654" lower_limit="561.5" upper_limit="1140.5"/>
                    <measurement group_id="O2" value="28" lower_limit="24" upper_limit="32"/>
                    <measurement group_id="O3" value="301" lower_limit="183" upper_limit="458"/>
                    <measurement group_id="O4" value="19" lower_limit="4" upper_limit="42"/>
                    <measurement group_id="O5" value="1117" lower_limit="551" upper_limit="1690"/>
                    <measurement group_id="O6" value="20" lower_limit="4" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="448" lower_limit="202" upper_limit="552"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O3" value="148" lower_limit="116" upper_limit="209"/>
                    <measurement group_id="O4" value="18" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O5" value="566" lower_limit="245" upper_limit="997"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="11"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="26"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="23"/>
                    <measurement group_id="O4" value="17" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="27"/>
                    <measurement group_id="O6" value="12.5" lower_limit="4" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="12" upper_limit="50.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="47"/>
                    <measurement group_id="O3" value="40" lower_limit="31" upper_limit="103"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="O5" value="32.5" lower_limit="4" upper_limit="84"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="47" upper_limit="117"/>
                    <measurement group_id="O2" value="25.5" lower_limit="4" upper_limit="47"/>
                    <measurement group_id="O3" value="82.5" lower_limit="39" upper_limit="116"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="18.5"/>
                    <measurement group_id="O5" value="39.5" lower_limit="25" upper_limit="76"/>
                    <measurement group_id="O6" value="17" lower_limit="4" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118" lower_limit="89" upper_limit="307"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="O3" value="133.5" lower_limit="42" upper_limit="242"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O5" value="278" lower_limit="161" upper_limit="525"/>
                    <measurement group_id="O6" value="17" lower_limit="4" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.5" lower_limit="129.5" upper_limit="246"/>
                    <measurement group_id="O2" value="32" lower_limit="4" upper_limit="60"/>
                    <measurement group_id="O3" value="75" lower_limit="44" upper_limit="236"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O5" value="269" lower_limit="128" upper_limit="500"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.5" lower_limit="31" upper_limit="218"/>
                    <measurement group_id="O2" value="18" lower_limit="4" upper_limit="60"/>
                    <measurement group_id="O3" value="47" lower_limit="24" upper_limit="95"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="29"/>
                    <measurement group_id="O5" value="126" lower_limit="61" upper_limit="296"/>
                    <measurement group_id="O6" value="10.5" lower_limit="4" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="4" upper_limit="41"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O3" value="14" lower_limit="4" upper_limit="22"/>
                    <measurement group_id="O4" value="17.5" lower_limit="4" upper_limit="45"/>
                    <measurement group_id="O5" value="19.5" lower_limit="4" upper_limit="37"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" lower_limit="4" upper_limit="88"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O3" value="43" lower_limit="17" upper_limit="75"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="46"/>
                    <measurement group_id="O5" value="44.5" lower_limit="4" upper_limit="69"/>
                    <measurement group_id="O6" value="5" lower_limit="4" upper_limit="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" lower_limit="32" upper_limit="201"/>
                    <measurement group_id="O2" value="84.5" lower_limit="33" upper_limit="136"/>
                    <measurement group_id="O3" value="150.5" lower_limit="69" upper_limit="253.5"/>
                    <measurement group_id="O4" value="25" lower_limit="4" upper_limit="53"/>
                    <measurement group_id="O5" value="300" lower_limit="202" upper_limit="519"/>
                    <measurement group_id="O6" value="18" lower_limit="4" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263" lower_limit="94" upper_limit="305"/>
                    <measurement group_id="O2" value="20" lower_limit="4" upper_limit="65"/>
                    <measurement group_id="O3" value="182" lower_limit="67" upper_limit="393"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="29"/>
                    <measurement group_id="O5" value="732" lower_limit="498" upper_limit="946"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381.5" lower_limit="223.5" upper_limit="561.5"/>
                    <measurement group_id="O2" value="46.5" lower_limit="32" upper_limit="61"/>
                    <measurement group_id="O3" value="171" lower_limit="84" upper_limit="514"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="38"/>
                    <measurement group_id="O5" value="939" lower_limit="534" upper_limit="1537"/>
                    <measurement group_id="O6" value="17.5" lower_limit="4" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.5" lower_limit="66" upper_limit="380"/>
                    <measurement group_id="O2" value="18" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O3" value="126" lower_limit="101" upper_limit="148"/>
                    <measurement group_id="O4" value="17" lower_limit="4" upper_limit="32"/>
                    <measurement group_id="O5" value="453" lower_limit="281" upper_limit="768"/>
                    <measurement group_id="O6" value="11" lower_limit="4" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="47" upper_limit="74.5"/>
                    <measurement group_id="O2" value="55" lower_limit="4" upper_limit="161"/>
                    <measurement group_id="O3" value="61" lower_limit="19" upper_limit="218"/>
                    <measurement group_id="O4" value="188.5" lower_limit="66" upper_limit="272"/>
                    <measurement group_id="O5" value="48.5" lower_limit="17" upper_limit="101"/>
                    <measurement group_id="O6" value="44.5" lower_limit="19" upper_limit="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270.5" lower_limit="224" upper_limit="408.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="73"/>
                    <measurement group_id="O3" value="389" lower_limit="207" upper_limit="735"/>
                    <measurement group_id="O4" value="151" lower_limit="79" upper_limit="278"/>
                    <measurement group_id="O5" value="232" lower_limit="46" upper_limit="491"/>
                    <measurement group_id="O6" value="43" lower_limit="10.5" upper_limit="148.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="563" lower_limit="541" upper_limit="1023"/>
                    <measurement group_id="O2" value="115" lower_limit="4" upper_limit="226"/>
                    <measurement group_id="O3" value="902" lower_limit="397.5" upper_limit="2177"/>
                    <measurement group_id="O4" value="132.5" lower_limit="54.5" upper_limit="398"/>
                    <measurement group_id="O5" value="156.5" lower_limit="76" upper_limit="481"/>
                    <measurement group_id="O6" value="71.5" lower_limit="18" upper_limit="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1236" lower_limit="886" upper_limit="3361"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="111"/>
                    <measurement group_id="O3" value="1828" lower_limit="462" upper_limit="3273"/>
                    <measurement group_id="O4" value="253" lower_limit="45" upper_limit="463"/>
                    <measurement group_id="O5" value="738.5" lower_limit="422" upper_limit="1663"/>
                    <measurement group_id="O6" value="46.5" lower_limit="17" upper_limit="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2219.5" lower_limit="1183" upper_limit="3234"/>
                    <measurement group_id="O2" value="24.5" lower_limit="4" upper_limit="45"/>
                    <measurement group_id="O3" value="608" lower_limit="361" upper_limit="1433"/>
                    <measurement group_id="O4" value="149.5" lower_limit="97" upper_limit="340"/>
                    <measurement group_id="O5" value="560" lower_limit="192" upper_limit="1563"/>
                    <measurement group_id="O6" value="55.5" lower_limit="25.5" upper_limit="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="869" lower_limit="202" upper_limit="1422"/>
                    <measurement group_id="O2" value="32" lower_limit="4" upper_limit="33"/>
                    <measurement group_id="O3" value="439" lower_limit="218" upper_limit="620"/>
                    <measurement group_id="O4" value="174" lower_limit="46" upper_limit="248"/>
                    <measurement group_id="O5" value="301" lower_limit="137" upper_limit="602"/>
                    <measurement group_id="O6" value="22" lower_limit="4" upper_limit="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="4" upper_limit="20.5"/>
                    <measurement group_id="O2" value="20" lower_limit="4" upper_limit="73"/>
                    <measurement group_id="O3" value="8" lower_limit="4" upper_limit="38"/>
                    <measurement group_id="O4" value="18" lower_limit="4" upper_limit="43"/>
                    <measurement group_id="O5" value="9.5" lower_limit="4" upper_limit="47"/>
                    <measurement group_id="O6" value="20" lower_limit="4" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34" lower_limit="18" upper_limit="40.5"/>
                    <measurement group_id="O2" value="17" lower_limit="4" upper_limit="47"/>
                    <measurement group_id="O3" value="58" lower_limit="24" upper_limit="74"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O5" value="40.5" lower_limit="17" upper_limit="98"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132" lower_limit="45" upper_limit="150"/>
                    <measurement group_id="O2" value="25.5" lower_limit="4" upper_limit="47"/>
                    <measurement group_id="O3" value="152.5" lower_limit="79" upper_limit="215"/>
                    <measurement group_id="O4" value="25.5" lower_limit="4" upper_limit="52.5"/>
                    <measurement group_id="O5" value="125.5" lower_limit="71" upper_limit="216"/>
                    <measurement group_id="O6" value="17" lower_limit="4" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276" lower_limit="117" upper_limit="889"/>
                    <measurement group_id="O2" value="37" lower_limit="4" upper_limit="87"/>
                    <measurement group_id="O3" value="375.5" lower_limit="230" upper_limit="805"/>
                    <measurement group_id="O4" value="40" lower_limit="4" upper_limit="84"/>
                    <measurement group_id="O5" value="915" lower_limit="471" upper_limit="1575"/>
                    <measurement group_id="O6" value="18" lower_limit="4" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359.5" lower_limit="255" upper_limit="556.5"/>
                    <measurement group_id="O2" value="62.5" lower_limit="4" upper_limit="121"/>
                    <measurement group_id="O3" value="176" lower_limit="75" upper_limit="327"/>
                    <measurement group_id="O4" value="26" lower_limit="4" upper_limit="65"/>
                    <measurement group_id="O5" value="792" lower_limit="421" upper_limit="1060"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167" lower_limit="75" upper_limit="191"/>
                    <measurement group_id="O2" value="19" lower_limit="4" upper_limit="35"/>
                    <measurement group_id="O3" value="77" lower_limit="23" upper_limit="134"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="40"/>
                    <measurement group_id="O5" value="272" lower_limit="142" upper_limit="358"/>
                    <measurement group_id="O6" value="18" lower_limit="4" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="4" upper_limit="40"/>
                    <measurement group_id="O2" value="17" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O3" value="25" lower_limit="6" upper_limit="61"/>
                    <measurement group_id="O4" value="43" lower_limit="4" upper_limit="80"/>
                    <measurement group_id="O5" value="27.5" lower_limit="4" upper_limit="54"/>
                    <measurement group_id="O6" value="12" lower_limit="4" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.5" lower_limit="62.5" upper_limit="155.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O3" value="227" lower_limit="65" upper_limit="469"/>
                    <measurement group_id="O4" value="22" lower_limit="4" upper_limit="71"/>
                    <measurement group_id="O5" value="163" lower_limit="100" upper_limit="239"/>
                    <measurement group_id="O6" value="29.5" lower_limit="4" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="60" upper_limit="75"/>
                    <measurement group_id="O2" value="41" lower_limit="32" upper_limit="50"/>
                    <measurement group_id="O3" value="124.5" lower_limit="64.5" upper_limit="284"/>
                    <measurement group_id="O4" value="13.5" lower_limit="4" upper_limit="65"/>
                    <measurement group_id="O5" value="86.5" lower_limit="27" upper_limit="154"/>
                    <measurement group_id="O6" value="30" lower_limit="4" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406" lower_limit="406" upper_limit="1923"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O3" value="649" lower_limit="245" upper_limit="1982"/>
                    <measurement group_id="O4" value="17" lower_limit="4" upper_limit="72"/>
                    <measurement group_id="O5" value="1355.5" lower_limit="917" upper_limit="2882"/>
                    <measurement group_id="O6" value="19" lower_limit="4" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213" lower_limit="75" upper_limit="378.5"/>
                    <measurement group_id="O2" value="17.5" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O3" value="147" lower_limit="58" upper_limit="339"/>
                    <measurement group_id="O4" value="20.5" lower_limit="4" upper_limit="46"/>
                    <measurement group_id="O5" value="399" lower_limit="135" upper_limit="664"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129" lower_limit="18" upper_limit="304"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="73"/>
                    <measurement group_id="O3" value="57" lower_limit="37" upper_limit="115"/>
                    <measurement group_id="O4" value="32" lower_limit="4" upper_limit="62"/>
                    <measurement group_id="O5" value="107" lower_limit="65" upper_limit="180"/>
                    <measurement group_id="O6" value="30.5" lower_limit="5" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="98.5"/>
                    <measurement group_id="O2" value="103" lower_limit="4" upper_limit="244"/>
                    <measurement group_id="O3" value="19" lower_limit="4" upper_limit="41"/>
                    <measurement group_id="O4" value="10.5" lower_limit="4" upper_limit="73"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="29"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="10.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="506"/>
                    <measurement group_id="O3" value="14" lower_limit="4" upper_limit="83"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="23"/>
                    <measurement group_id="O5" value="19" lower_limit="4" upper_limit="171"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O2" value="1375.5" lower_limit="4" upper_limit="2747"/>
                    <measurement group_id="O3" value="208" lower_limit="11" upper_limit="689"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="37"/>
                    <measurement group_id="O5" value="342" lower_limit="133" upper_limit="769"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="937" lower_limit="17" upper_limit="1644"/>
                    <measurement group_id="O2" value="213" lower_limit="20" upper_limit="373"/>
                    <measurement group_id="O3" value="1544" lower_limit="787" upper_limit="2630"/>
                    <measurement group_id="O4" value="18" lower_limit="4" upper_limit="200"/>
                    <measurement group_id="O5" value="3575.5" lower_limit="2450" upper_limit="6212"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="373.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="168" lower_limit="4" upper_limit="727"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="104"/>
                    <measurement group_id="O5" value="1426" lower_limit="653" upper_limit="2820"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="4" upper_limit="712"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="296" lower_limit="13" upper_limit="743"/>
                    <measurement group_id="O4" value="45" lower_limit="4" upper_limit="233"/>
                    <measurement group_id="O5" value="497" lower_limit="34" upper_limit="900"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="26"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="68"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O3" value="19" lower_limit="4" upper_limit="74"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="26"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="41"/>
                    <measurement group_id="O2" value="26" lower_limit="4" upper_limit="48"/>
                    <measurement group_id="O3" value="35" lower_limit="4" upper_limit="85"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="10.5"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="25"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="46" upper_limit="93"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="64.5" lower_limit="17" upper_limit="148"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="32.5" lower_limit="4" upper_limit="66"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" lower_limit="17.5" upper_limit="62.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="60"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="19" lower_limit="4" upper_limit="33"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="4" upper_limit="32"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="11"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="19.5" lower_limit="4" upper_limit="54.5"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="17.5"/>
                    <measurement group_id="O5" value="17.5" lower_limit="4" upper_limit="33"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="24"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="34" lower_limit="8" upper_limit="67"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="10.5" upper_limit="55.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="45" lower_limit="16" upper_limit="79"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="21"/>
                    <measurement group_id="O2" value="17" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="34"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="16.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="17" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="11" lower_limit="4" upper_limit="23.5"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="17" upper_limit="32"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="17" lower_limit="4" upper_limit="24"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="19.5" lower_limit="4" upper_limit="61"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="22"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="24"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="10.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="23"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O4" value="17" lower_limit="4" upper_limit="30"/>
                    <measurement group_id="O5" value="18.5" lower_limit="4" upper_limit="26"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="19" upper_limit="32"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="21" lower_limit="6.5" upper_limit="44.5"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="O5" value="18" lower_limit="4" upper_limit="32"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="27.5" lower_limit="17" upper_limit="45"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O5" value="40.5" lower_limit="19" upper_limit="82"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="4.5" upper_limit="28.5"/>
                    <measurement group_id="O2" value="17.5" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O4" value="11" lower_limit="4" upper_limit="23"/>
                    <measurement group_id="O5" value="49" lower_limit="20" upper_limit="70"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="4" upper_limit="59"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="32"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="26"/>
                    <measurement group_id="O5" value="25" lower_limit="8" upper_limit="44"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="4" upper_limit="25"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="24" lower_limit="4" upper_limit="59"/>
                    <measurement group_id="O4" value="13.5" lower_limit="4" upper_limit="136"/>
                    <measurement group_id="O5" value="17.5" lower_limit="4" upper_limit="32"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5" lower_limit="34.5" upper_limit="87.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O3" value="102" lower_limit="40" upper_limit="230"/>
                    <measurement group_id="O4" value="18" lower_limit="4" upper_limit="234"/>
                    <measurement group_id="O5" value="53" lower_limit="17" upper_limit="246"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="4" upper_limit="117"/>
                    <measurement group_id="O2" value="26" lower_limit="4" upper_limit="48"/>
                    <measurement group_id="O3" value="112" lower_limit="21.5" upper_limit="212"/>
                    <measurement group_id="O4" value="44" lower_limit="10.5" upper_limit="334.5"/>
                    <measurement group_id="O5" value="42" lower_limit="4" upper_limit="89"/>
                    <measurement group_id="O6" value="20" lower_limit="4" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246" lower_limit="116" upper_limit="288"/>
                    <measurement group_id="O2" value="34" lower_limit="4" upper_limit="65"/>
                    <measurement group_id="O3" value="212.5" lower_limit="94" upper_limit="698"/>
                    <measurement group_id="O4" value="50" lower_limit="5" upper_limit="361"/>
                    <measurement group_id="O5" value="185.5" lower_limit="61" upper_limit="463"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.5" lower_limit="76" upper_limit="214"/>
                    <measurement group_id="O2" value="14" lower_limit="4" upper_limit="24"/>
                    <measurement group_id="O3" value="34" lower_limit="19" upper_limit="338"/>
                    <measurement group_id="O4" value="46" lower_limit="4" upper_limit="534"/>
                    <measurement group_id="O5" value="69" lower_limit="32" upper_limit="277"/>
                    <measurement group_id="O6" value="18.5" lower_limit="4" upper_limit="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="4" upper_limit="156"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O3" value="30" lower_limit="18" upper_limit="112"/>
                    <measurement group_id="O4" value="29" lower_limit="4" upper_limit="169"/>
                    <measurement group_id="O5" value="46" lower_limit="4" upper_limit="77"/>
                    <measurement group_id="O6" value="11.5" lower_limit="4" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="5" upper_limit="31"/>
                    <measurement group_id="O2" value="18" lower_limit="18" upper_limit="29"/>
                    <measurement group_id="O3" value="20" lower_limit="4" upper_limit="55"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="41"/>
                    <measurement group_id="O5" value="8" lower_limit="4" upper_limit="38"/>
                    <measurement group_id="O6" value="22.5" lower_limit="4" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" lower_limit="11" upper_limit="38"/>
                    <measurement group_id="O2" value="17" lower_limit="4" upper_limit="45"/>
                    <measurement group_id="O3" value="19" lower_limit="4" upper_limit="75"/>
                    <measurement group_id="O4" value="17" lower_limit="4" upper_limit="32"/>
                    <measurement group_id="O5" value="26" lower_limit="4" upper_limit="57"/>
                    <measurement group_id="O6" value="28.5" lower_limit="4" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="6" upper_limit="26"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="51.5" lower_limit="15" upper_limit="101"/>
                    <measurement group_id="O4" value="32.5" lower_limit="4.5" upper_limit="67"/>
                    <measurement group_id="O5" value="8" lower_limit="4" upper_limit="61"/>
                    <measurement group_id="O6" value="12.5" lower_limit="4" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="31" upper_limit="153"/>
                    <measurement group_id="O2" value="66" lower_limit="31" upper_limit="117"/>
                    <measurement group_id="O3" value="87" lower_limit="31" upper_limit="256"/>
                    <measurement group_id="O4" value="11" lower_limit="4" upper_limit="119"/>
                    <measurement group_id="O5" value="309" lower_limit="137" upper_limit="532"/>
                    <measurement group_id="O6" value="7.5" lower_limit="4" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="57.5" upper_limit="108"/>
                    <measurement group_id="O2" value="50" lower_limit="40" upper_limit="60"/>
                    <measurement group_id="O3" value="23" lower_limit="4" upper_limit="104"/>
                    <measurement group_id="O4" value="36" lower_limit="4" upper_limit="59"/>
                    <measurement group_id="O5" value="88" lower_limit="35" upper_limit="225"/>
                    <measurement group_id="O6" value="22" lower_limit="4" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="60"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="5" lower_limit="4" upper_limit="57"/>
                    <measurement group_id="O4" value="23" lower_limit="4" upper_limit="54"/>
                    <measurement group_id="O5" value="24" lower_limit="4" upper_limit="76"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD4+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L-/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="4" upper_limit="52.5"/>
                    <measurement group_id="O2" value="20" lower_limit="4" upper_limit="61"/>
                    <measurement group_id="O3" value="47" lower_limit="4" upper_limit="64"/>
                    <measurement group_id="O4" value="51" lower_limit="4" upper_limit="99"/>
                    <measurement group_id="O5" value="70" lower_limit="38" upper_limit="157"/>
                    <measurement group_id="O6" value="14.5" lower_limit="4" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" lower_limit="17.5" upper_limit="114"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="83"/>
                    <measurement group_id="O3" value="59" lower_limit="12" upper_limit="363"/>
                    <measurement group_id="O4" value="46" lower_limit="6" upper_limit="482"/>
                    <measurement group_id="O5" value="78" lower_limit="32" upper_limit="248"/>
                    <measurement group_id="O6" value="25.5" lower_limit="4" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" lower_limit="45" upper_limit="61"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="52" lower_limit="4" upper_limit="201.5"/>
                    <measurement group_id="O4" value="33.5" lower_limit="4" upper_limit="270"/>
                    <measurement group_id="O5" value="47" lower_limit="4" upper_limit="138"/>
                    <measurement group_id="O6" value="26.5" lower_limit="4" upper_limit="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191" lower_limit="89" upper_limit="408"/>
                    <measurement group_id="O2" value="34" lower_limit="31" upper_limit="97"/>
                    <measurement group_id="O3" value="273" lower_limit="131" upper_limit="720"/>
                    <measurement group_id="O4" value="27" lower_limit="4" upper_limit="261"/>
                    <measurement group_id="O5" value="495.5" lower_limit="267" upper_limit="1466"/>
                    <measurement group_id="O6" value="19" lower_limit="4" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="4" upper_limit="48.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="32" lower_limit="4" upper_limit="267"/>
                    <measurement group_id="O4" value="51.5" lower_limit="17" upper_limit="144"/>
                    <measurement group_id="O5" value="129" lower_limit="40" upper_limit="276"/>
                    <measurement group_id="O6" value="19.5" lower_limit="4" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5" lower_limit="31" upper_limit="117"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="60"/>
                    <measurement group_id="O3" value="30" lower_limit="4" upper_limit="85"/>
                    <measurement group_id="O4" value="34" lower_limit="4" upper_limit="92"/>
                    <measurement group_id="O5" value="31" lower_limit="4" upper_limit="126"/>
                    <measurement group_id="O6" value="55" lower_limit="32.5" upper_limit="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing at Least 2 Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing at Least 2 Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD8-ALL doubles, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="63.5" upper_limit="269"/>
                    <measurement group_id="O2" value="44" lower_limit="44" upper_limit="135"/>
                    <measurement group_id="O3" value="99" lower_limit="75" upper_limit="159"/>
                    <measurement group_id="O4" value="110.5" lower_limit="59" upper_limit="326"/>
                    <measurement group_id="O5" value="73" lower_limit="44" upper_limit="144"/>
                    <measurement group_id="O6" value="69.5" lower_limit="44" upper_limit="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-ALL doubles, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="80.5" upper_limit="141"/>
                    <measurement group_id="O2" value="72" lower_limit="45" upper_limit="77"/>
                    <measurement group_id="O3" value="222" lower_limit="146" upper_limit="329"/>
                    <measurement group_id="O4" value="62" lower_limit="44" upper_limit="324"/>
                    <measurement group_id="O5" value="74.5" lower_limit="44" upper_limit="144"/>
                    <measurement group_id="O6" value="92.5" lower_limit="53" upper_limit="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-ALL doubles, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="44" upper_limit="64"/>
                    <measurement group_id="O2" value="81.5" lower_limit="44" upper_limit="119"/>
                    <measurement group_id="O3" value="243" lower_limit="101" upper_limit="385"/>
                    <measurement group_id="O4" value="153.5" lower_limit="75.5" upper_limit="1064"/>
                    <measurement group_id="O5" value="80" lower_limit="44" upper_limit="150"/>
                    <measurement group_id="O6" value="77.5" lower_limit="59" upper_limit="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-ALL doubles, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" lower_limit="118" upper_limit="134"/>
                    <measurement group_id="O2" value="76" lower_limit="44" upper_limit="93"/>
                    <measurement group_id="O3" value="347" lower_limit="97" upper_limit="604"/>
                    <measurement group_id="O4" value="108" lower_limit="59" upper_limit="295"/>
                    <measurement group_id="O5" value="72.5" lower_limit="57" upper_limit="149"/>
                    <measurement group_id="O6" value="75.5" lower_limit="44" upper_limit="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-ALL doubles, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" lower_limit="55.5" upper_limit="233"/>
                    <measurement group_id="O2" value="118" lower_limit="69" upper_limit="167"/>
                    <measurement group_id="O3" value="189" lower_limit="60" upper_limit="367"/>
                    <measurement group_id="O4" value="161" lower_limit="84" upper_limit="491"/>
                    <measurement group_id="O5" value="96" lower_limit="44" upper_limit="245"/>
                    <measurement group_id="O6" value="71" lower_limit="44" upper_limit="157.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8-ALL doubles, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347.5" lower_limit="170" upper_limit="572"/>
                    <measurement group_id="O2" value="78" lower_limit="44" upper_limit="91"/>
                    <measurement group_id="O3" value="259" lower_limit="61" upper_limit="312"/>
                    <measurement group_id="O4" value="119" lower_limit="44" upper_limit="390"/>
                    <measurement group_id="O5" value="110" lower_limit="69" upper_limit="248"/>
                    <measurement group_id="O6" value="71.5" lower_limit="49.5" upper_limit="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing 2 or More Immune Markers Among 6</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a), CD40-ligand (CD40-L), Interleukin-17 (IL-17) and/or Interleukin-17 (IL-17).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing 2 or More Immune Markers Among 6</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a), CD40-ligand (CD40-L), Interleukin-17 (IL-17) and/or Interleukin-17 (IL-17).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD8-At least 2, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106" lower_limit="76.5" upper_limit="282"/>
                    <measurement group_id="O2" value="57" lower_limit="57" upper_limit="148"/>
                    <measurement group_id="O3" value="143" lower_limit="88" upper_limit="172"/>
                    <measurement group_id="O4" value="151.5" lower_limit="81" upper_limit="339"/>
                    <measurement group_id="O5" value="96" lower_limit="57" upper_limit="157"/>
                    <measurement group_id="O6" value="85.5" lower_limit="57" upper_limit="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8- At least 2, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.5" lower_limit="93.5" upper_limit="154"/>
                    <measurement group_id="O2" value="85" lower_limit="58" upper_limit="90"/>
                    <measurement group_id="O3" value="245" lower_limit="159" upper_limit="369"/>
                    <measurement group_id="O4" value="75" lower_limit="57" upper_limit="337"/>
                    <measurement group_id="O5" value="116" lower_limit="71" upper_limit="158"/>
                    <measurement group_id="O6" value="124" lower_limit="88" upper_limit="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8- At least 2, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="57" upper_limit="77"/>
                    <measurement group_id="O2" value="109" lower_limit="86" upper_limit="132"/>
                    <measurement group_id="O3" value="256" lower_limit="114" upper_limit="410.5"/>
                    <measurement group_id="O4" value="166.5" lower_limit="88.5" upper_limit="1077"/>
                    <measurement group_id="O5" value="96" lower_limit="73" upper_limit="163"/>
                    <measurement group_id="O6" value="106.5" lower_limit="77" upper_limit="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8- At least 2, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139" lower_limit="131" upper_limit="147"/>
                    <measurement group_id="O2" value="89" lower_limit="57" upper_limit="106"/>
                    <measurement group_id="O3" value="362" lower_limit="110" upper_limit="617"/>
                    <measurement group_id="O4" value="121" lower_limit="72" upper_limit="308"/>
                    <measurement group_id="O5" value="85.5" lower_limit="70" upper_limit="162"/>
                    <measurement group_id="O6" value="103.5" lower_limit="58" upper_limit="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8- At least 2, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="68.5" upper_limit="246"/>
                    <measurement group_id="O2" value="131" lower_limit="82" upper_limit="180"/>
                    <measurement group_id="O3" value="202" lower_limit="89" upper_limit="380"/>
                    <measurement group_id="O4" value="174" lower_limit="97" upper_limit="504"/>
                    <measurement group_id="O5" value="111" lower_limit="76" upper_limit="270"/>
                    <measurement group_id="O6" value="106.5" lower_limit="57" upper_limit="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD8- At least 2, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="403.5" lower_limit="183" upper_limit="585"/>
                    <measurement group_id="O2" value="91" lower_limit="57" upper_limit="151"/>
                    <measurement group_id="O3" value="272" lower_limit="74" upper_limit="379"/>
                    <measurement group_id="O4" value="133" lower_limit="76" upper_limit="403"/>
                    <measurement group_id="O5" value="137" lower_limit="83" upper_limit="291"/>
                    <measurement group_id="O6" value="124.5" lower_limit="81.5" upper_limit="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="14"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="62"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="25"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="41"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="48"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="4" upper_limit="99"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="38"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="33"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="4" upper_limit="46"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="25"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="32"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="14" lower_limit="4" upper_limit="24"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="33.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="23"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="55"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="36.5" lower_limit="4" upper_limit="84"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="168"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="21"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="42"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="24"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="13"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="51"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="56"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="21"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="37"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="17"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="21"/>
                    <measurement group_id="O2" value="24.5" lower_limit="4" upper_limit="45"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="21"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="23.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="26"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="26"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="54"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="22"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="24"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="41.5" lower_limit="4" upper_limit="79"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="28.5"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="25"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="36"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="21"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="21"/>
                    <measurement group_id="O2" value="16.5" lower_limit="4" upper_limit="29"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="14.5" lower_limit="4" upper_limit="46"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="76"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="4" upper_limit="88"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="35"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="29"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="4" upper_limit="412"/>
                    <measurement group_id="O2" value="143" lower_limit="4" upper_limit="178"/>
                    <measurement group_id="O3" value="29" lower_limit="4" upper_limit="203"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="139"/>
                    <measurement group_id="O5" value="7.5" lower_limit="4" upper_limit="130"/>
                    <measurement group_id="O6" value="25" lower_limit="4" upper_limit="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" lower_limit="4" upper_limit="68"/>
                    <measurement group_id="O2" value="110" lower_limit="93" upper_limit="390"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="413"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="183"/>
                    <measurement group_id="O6" value="26" lower_limit="4" upper_limit="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="4" upper_limit="113"/>
                    <measurement group_id="O2" value="161" lower_limit="83" upper_limit="239"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="23"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="78.5"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="71"/>
                    <measurement group_id="O6" value="99.5" lower_limit="4" upper_limit="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="203"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="216"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="293"/>
                    <measurement group_id="O4" value="43" lower_limit="4" upper_limit="125"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="127"/>
                    <measurement group_id="O6" value="13.5" lower_limit="4" upper_limit="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" lower_limit="4" upper_limit="163.5"/>
                    <measurement group_id="O2" value="44.5" lower_limit="4" upper_limit="85"/>
                    <measurement group_id="O3" value="101" lower_limit="4" upper_limit="345"/>
                    <measurement group_id="O4" value="85" lower_limit="4" upper_limit="270"/>
                    <measurement group_id="O5" value="61" lower_limit="4" upper_limit="153"/>
                    <measurement group_id="O6" value="36.5" lower_limit="4" upper_limit="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L+/IL2-/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="15" upper_limit="92"/>
                    <measurement group_id="O2" value="122" lower_limit="4" upper_limit="202"/>
                    <measurement group_id="O3" value="333" lower_limit="4" upper_limit="583"/>
                    <measurement group_id="O4" value="121" lower_limit="4" upper_limit="249"/>
                    <measurement group_id="O5" value="22" lower_limit="4" upper_limit="311"/>
                    <measurement group_id="O6" value="33.5" lower_limit="4" upper_limit="302.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="15.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="41"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="37"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="32"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="19"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="4" upper_limit="49"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="18"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="15.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="20"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2+/TNFa-/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="13"/>
                    <measurement group_id="O2" value="38" lower_limit="4" upper_limit="98"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="199.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="73"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="47"/>
                    <measurement group_id="O4" value="30" lower_limit="4" upper_limit="286"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="37"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="30.5" upper_limit="101"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O3" value="32" lower_limit="4" upper_limit="109"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="284"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="104"/>
                    <measurement group_id="O6" value="9" lower_limit="4" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="107"/>
                    <measurement group_id="O4" value="91.5" lower_limit="4" upper_limit="1024"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="39"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="4" upper_limit="66"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="53"/>
                    <measurement group_id="O3" value="28.5" lower_limit="4" upper_limit="285"/>
                    <measurement group_id="O4" value="28" lower_limit="4" upper_limit="228"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="30"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="4" upper_limit="144"/>
                    <measurement group_id="O2" value="35" lower_limit="4" upper_limit="66"/>
                    <measurement group_id="O3" value="29" lower_limit="4" upper_limit="149"/>
                    <measurement group_id="O4" value="58" lower_limit="4" upper_limit="432"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="39"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="4" upper_limit="264"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="184"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="101"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="27"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg-, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="4" upper_limit="80"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="61"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="36"/>
                    <measurement group_id="O4" value="7.5" lower_limit="4" upper_limit="37"/>
                    <measurement group_id="O5" value="25.5" lower_limit="4" upper_limit="57"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg-, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="4" upper_limit="61"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="59"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="82"/>
                    <measurement group_id="O5" value="20.5" lower_limit="4" upper_limit="39"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg-, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="80" lower_limit="4" upper_limit="156"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="67.5"/>
                    <measurement group_id="O4" value="47.5" lower_limit="6" upper_limit="123"/>
                    <measurement group_id="O5" value="20.5" lower_limit="4" upper_limit="67"/>
                    <measurement group_id="O6" value="24.5" lower_limit="4" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg-, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="4" upper_limit="128"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="69"/>
                    <measurement group_id="O3" value="36.5" lower_limit="4" upper_limit="112"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="43"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="27"/>
                    <measurement group_id="O6" value="5" lower_limit="4" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg-, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="4" upper_limit="54"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="89"/>
                    <measurement group_id="O4" value="18.5" lower_limit="4" upper_limit="90"/>
                    <measurement group_id="O5" value="20" lower_limit="4" upper_limit="56"/>
                    <measurement group_id="O6" value="4.5" lower_limit="4" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa+/IFNg-, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O4" value="4" lower_limit="4" upper_limit="42"/>
                    <measurement group_id="O5" value="4" lower_limit="4" upper_limit="60"/>
                    <measurement group_id="O6" value="4" lower_limit="4" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
        <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
        <time_frame>Prior to dose 1 (Day 0 - PRE), post-dose 1 (Days 7 – D7 and 30 – D30), post-dose 2 (Days 37 – D37, 60 – D60 and 210 – D210)</time_frame>
        <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>TB Treatment GSK 692342 Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O2">
            <title>TB Treatment Saline Group</title>
            <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O3">
            <title>TB Treated GSK 692342 Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O4">
            <title>TB Treated Saline Group</title>
            <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O5">
            <title>TB Naive GSK 692342 Group</title>
            <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
          <group group_id="O6">
            <title>TB Naive Saline Group</title>
            <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of M72-specific CD8+ T Cells Per Million Cells Expressing Any Combination of Immune Markers</title>
          <description>Immune markers expressed were among Interleukin-2 (IL-2), Interferon-gamma (IFN-g), Tumour necrosis factor-alpha (TNF-a) and/or CD40-ligand (CD40-L).</description>
          <population>The analysis was performed on the ATP cohort for immunogenicity which included all evaluable subjects who did not meet any of the criteria for elimination from ATP analysis,who complied with the procedures and intervals defined in the protocol and for whom data concerning immunogenicity endpoint measures were available at the time of each analysis.</population>
          <units>T cells/million cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD40L-/IL2-/TNFa-/IFNg+, PRE (N=4;3;15;22;30;30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="25.5" upper_limit="821"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="95"/>
                    <measurement group_id="O3" value="70" lower_limit="12" upper_limit="541"/>
                    <measurement group_id="O4" value="216.5" lower_limit="57" upper_limit="1831"/>
                    <measurement group_id="O5" value="54.5" lower_limit="4" upper_limit="159"/>
                    <measurement group_id="O6" value="78.5" lower_limit="25" upper_limit="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa-/IFNg+, D7 (N=4;3;13;15;26;28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="36.5" upper_limit="893.5"/>
                    <measurement group_id="O2" value="9" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O3" value="152" lower_limit="4" upper_limit="575"/>
                    <measurement group_id="O4" value="205" lower_limit="90" upper_limit="1660"/>
                    <measurement group_id="O5" value="69.5" lower_limit="43" upper_limit="830"/>
                    <measurement group_id="O6" value="90.5" lower_limit="4.5" upper_limit="484.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa-/IFNg+, D30 (N=5;2;16;16;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="26" upper_limit="163"/>
                    <measurement group_id="O2" value="118" lower_limit="4" upper_limit="232"/>
                    <measurement group_id="O3" value="127.5" lower_limit="13" upper_limit="327.5"/>
                    <measurement group_id="O4" value="386.5" lower_limit="27" upper_limit="1969.5"/>
                    <measurement group_id="O5" value="64.5" lower_limit="4" upper_limit="438"/>
                    <measurement group_id="O6" value="151.5" lower_limit="28" upper_limit="467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa-/IFNg+, D37 (N=5;3;18;19;34;34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="4" upper_limit="78"/>
                    <measurement group_id="O2" value="33" lower_limit="4" upper_limit="81"/>
                    <measurement group_id="O3" value="100.5" lower_limit="48" upper_limit="326"/>
                    <measurement group_id="O4" value="229" lower_limit="4" upper_limit="1022"/>
                    <measurement group_id="O5" value="46.5" lower_limit="4" upper_limit="179"/>
                    <measurement group_id="O6" value="83.5" lower_limit="4" upper_limit="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa-/IFNg+, D60 (N=4;2;15;18;31;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.5" lower_limit="55" upper_limit="824.5"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="4"/>
                    <measurement group_id="O3" value="70" lower_limit="4" upper_limit="1116"/>
                    <measurement group_id="O4" value="172" lower_limit="18" upper_limit="1492"/>
                    <measurement group_id="O5" value="13" lower_limit="4" upper_limit="65"/>
                    <measurement group_id="O6" value="59" lower_limit="4" upper_limit="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD40L-/IL2-/TNFa-/IFNg+, D210 (N=6;3;13;17;37;36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286.5" lower_limit="48" upper_limit="469"/>
                    <measurement group_id="O2" value="4" lower_limit="4" upper_limit="59"/>
                    <measurement group_id="O3" value="51" lower_limit="4" upper_limit="245"/>
                    <measurement group_id="O4" value="85" lower_limit="4" upper_limit="628"/>
                    <measurement group_id="O5" value="69" lower_limit="4" upper_limit="233"/>
                    <measurement group_id="O6" value="60" lower_limit="22" upper_limit="232.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited AEs: during the 7 day (Days 0-6), after each vaccine dose; Unsolicited AEs: during the 30 day (Days 0-29), after vaccination; SAEs: Up to day 210.</time_frame>
      <desc>Results presented per group consist of a summary of the events (SAEs and AEs other than SAEs, respectively) reported, compiling overall number of subjects with events across the different periods of assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>TB Treatment GSK 692342 Group</title>
          <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment, who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="E2">
          <title>TB Treatment Saline Group</title>
          <description>Subjects having completed the intensive phase of treatment, i.e. 2 to 4 months post initiation of treatment who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="E3">
          <title>TB Treated GSK 692342 Group</title>
          <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who during this study received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="E4">
          <title>TB Treated Saline Group</title>
          <description>Subjects having successfully completed treatment for TB disease at least 1 year prior to the study, who in this study received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="E5">
          <title>TB Naive GSK 692342 Group</title>
          <description>Subjects unaffected by tuberculosis who received the GSK 692342 vaccine according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
        <group group_id="E6">
          <title>TB Naive Saline Group</title>
          <description>Subjects unaffected by tuberculosis who received a placebo (physiological saline) according to a 2-dose schedule at Months 0 and 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Headache (solicited)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Temperature/(Axillary)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to a safety signal found at a planned interim safety review, further conduct of this safety study is not recommended hence the study was terminated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

